Huixin Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Huixin Shen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Miao Qu
Neurology Department, Xuanwu Hospital of Capital Medical University, China
2 shared publications - Chuming Yan
Neurology Department, Xuanwu Hospital of Capital Medical University, Beijing, People’s Republic of China
1 shared publication Chunqiu Fan
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China
1 shared publicationHong Zhao
Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China
1 shared publicationJian Chen
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China
1 shared publicationJiangang Duan
Department of Emergency, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 22, 1-12
Discriminative Plasma Lipidomic Signatures of Dementia with Lewy Bodies and Alzheimer’s Disease: A Targeted Mass Spectrometry and Machine Learning Approach
Background: Dementia with Lewy bodies (DLB) exhibits a more aggressive progression and poorer prognosis than Alzheimer’s disease (AD), yet clinical differentiation remains challenging. Dysregulated lipid metabolism, implicated in α-synuclein aggregation and neuroinflammation, may offer specific biomarkers for distinguishing DLB and AD. Methods: This cross-sectional study implemented targeted lipidomic profiling to comprehensively characterize plasma lipidomes in a cohort comprising 50 DLB patients and 56 AD patients. Five machine learning algorithms - least absolute shrinkage and selection operator (LASSO) regression, support vector machine (SVM), random forest (RF), recursive feature elimination (RFE), and stepwise regression - were systematically applied for biomarker discovery. Results: Significant alterations were observed in 7 lipid classes and 65 specific lipid species in DLB compared to AD. DLB plasma exhibited marked elevations in sphingolipids (total Cer, Hex1Cer, SM), lysophospholipids (LPC, LPE), phosphatidic acid (PA), alongside significant reductions in 45 triacylglycerol (TG) species compared to AD. Five machine learning algorithms consistently identified PA(16:0_16:0) and PA(16:0_20:4) as core discriminators between DLB and AD. The LASSO regression model demonstrated superior generalizability in the test set (AUC=0.916), selecting a 11-lipid panel dominated by PA species, alongside PC(18:0_20:4), ChE(22:4), Hex2Cer(d18:1_22:0), and PE species. Conclusion: This first comprehensive targeted lipidomics study reveals distinct plasma lipid signatures differentiating DLB from AD, characterized by upregulated sphingolipids, lysophospholipids, and PA, and downregulated TG. Machine learning identified a 11-lipid biomarker panel, highlighting profound disturbances in glycerophospholipid metabolism. These findings provide novel molecular insights into DLB pathogenesis and a promising diagnostic tool for diagnosis.
- 1 March 2026
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 22, 1-12
Open AccessDiscriminative Plasma Lipidomic Signatures of Dementia with Lewy Bodies and Alzheimer’s Disease: A Targeted Mass Spectrometry and Machine Learning Approach
Background: Dementia with Lewy bodies (DLB) exhibits a more aggressive progression and poorer prognosis than Alzheimer’s disease (AD), yet clinical differentiation remains challenging. Dysregulated lipid metabolism, implicated in α-synuclein aggregation and neuroinflammation, may offer specific biomarkers for distinguishing DLB and AD. Methods: This cross-sectional study implemented targeted lipidomic profiling to comprehensively characterize plasma lipidomes in a cohort comprising 50 DLB patients and 56 AD patients. Five machine learning algorithms - least absolute shrinkage and selection operator (LASSO) regression, support vector machine (SVM), random forest (RF), recursive feature elimination (RFE), and stepwise regression - were systematically applied for biomarker discovery. Results: Significant alterations were observed in 7 lipid classes and 65 specific lipid species in DLB compared to AD. DLB plasma exhibited marked elevations in sphingolipids (total Cer, Hex1Cer, SM), lysophospholipids (LPC, LPE), phosphatidic acid (PA), alongside significant reductions in 45 triacylglycerol (TG) species compared to AD. Five machine learning algorithms consistently identified PA(16:0_16:0) and PA(16:0_20:4) as core discriminators between DLB and AD. The LASSO regression model demonstrated superior generalizability in the test set (AUC=0.916), selecting a 11-lipid panel dominated by PA species, alongside PC(18:0_20:4), ChE(22:4), Hex2Cer(d18:1_22:0), and PE species. Conclusion: This first comprehensive targeted lipidomics study reveals distinct plasma lipid signatures differentiating DLB from AD, characterized by upregulated sphingolipids, lysophospholipids, and PA, and downregulated TG. Machine learning identified a 11-lipid biomarker panel, highlighting profound disturbances in glycerophospholipid metabolism. These findings provide novel molecular insights into DLB pathogenesis and a promising diagnostic tool for diagnosis.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 477-489
Characteristics of Gut Microbiota and Plasma Metabolites in Patients with Post-Stroke Depression
Purpose: The changes in gut microbiota and plasma metabolites have been proposed to play a key role in post stroke depression (PSD), but clinical study based on combined omics is still in lack. This study aimed to investigate the characteristics of gut microbiota and plasma metabolites in patients 3 months after the onset of acute ischemic stroke (AIS), compare PSD and non-PSD groups, and explore possible diagnostic biomarkers. Patients and Methods: Seventy patients with stroke were included at 3 months after AIS onset. Plasma and fecal samples were collected. Gut microbiome was examined using 16S rRNA sequencing, and plasma metabolites were assessed via targeted liquid chromatography-mass spectrometry. Results: Of the 70 patients with ischemic stroke, 25 (35.71%) were diagnosed with PSD. At the genus level, patients with PSD had increased abundance of Parabacteroides, Pyramidobacter, Anaeroglobus, Haliangium, Staphylococcus, CAG− 56, Shuttleworthia, and Epulopiscium, and decreased levels of the Eubacterium eligens group and Prevotella. In patients with PSD, 12 plasma metabolites were altered, with cortisol and pyroglutamic acid levels increased, while 2-phosphoglyceric acid, 3-phosphoglycerate, phosphorylcholine, tryptophan, caffeine, N-methylalanine, ornithine, serotonin, theophylline, and vanillic acid were decreased. Enriched metabolic pathways included glutathione, tryptophan, and caffeine metabolism. Furthermore, significant correlations were observed between gut microbial dysregulation and major plasma metabolite alterations. The areas under the curve values of gut microbiota, plasma metabolites, and the combined dataset for PSD diagnosis were 0.704, 0.875, and 0.940, respectively. Conclusion: This study identified the characteristics of gut microbiota and plasma metabolites as well as a panel of combined biomarkers in 3-month PSD, possibly providing a new theoretical framework for diagnosis and treatment.
- 1 March 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 477-489
Open AccessCharacteristics of Gut Microbiota and Plasma Metabolites in Patients with Post-Stroke Depression
Purpose: The changes in gut microbiota and plasma metabolites have been proposed to play a key role in post stroke depression (PSD), but clinical study based on combined omics is still in lack. This study aimed to investigate the characteristics of gut microbiota and plasma metabolites in patients 3 months after the onset of acute ischemic stroke (AIS), compare PSD and non-PSD groups, and explore possible diagnostic biomarkers. Patients and Methods: Seventy patients with stroke were included at 3 months after AIS onset. Plasma and fecal samples were collected. Gut microbiome was examined using 16S rRNA sequencing, and plasma metabolites were assessed via targeted liquid chromatography-mass spectrometry. Results: Of the 70 patients with ischemic stroke, 25 (35.71%) were diagnosed with PSD. At the genus level, patients with PSD had increased abundance of Parabacteroides, Pyramidobacter, Anaeroglobus, Haliangium, Staphylococcus, CAG− 56, Shuttleworthia, and Epulopiscium, and decreased levels of the Eubacterium eligens group and Prevotella. In patients with PSD, 12 plasma metabolites were altered, with cortisol and pyroglutamic acid levels increased, while 2-phosphoglyceric acid, 3-phosphoglycerate, phosphorylcholine, tryptophan, caffeine, N-methylalanine, ornithine, serotonin, theophylline, and vanillic acid were decreased. Enriched metabolic pathways included glutathione, tryptophan, and caffeine metabolism. Furthermore, significant correlations were observed between gut microbial dysregulation and major plasma metabolite alterations. The areas under the curve values of gut microbiota, plasma metabolites, and the combined dataset for PSD diagnosis were 0.704, 0.875, and 0.940, respectively. Conclusion: This study identified the characteristics of gut microbiota and plasma metabolites as well as a panel of combined biomarkers in 3-month PSD, possibly providing a new theoretical framework for diagnosis and treatment.
- Open Access
- 1 April 2021
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 17, 1195-1206
Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia
Background and Objective: Essential thrombocythemia (ET) is a rare cause of cerebral venous sinus thrombosis (CVST). Analysis of the risk factors and treatment therapies of CVST in ET has yielded controversial findings. Subjects and Methods: We retrospectively investigated the clinical characteristics of CVST events in ET and compared baseline characteristics, causative factors, hematological effects, and treatments between ET patients with and without CVST. Results: Overall, 91 of 115 patients who met the ET diagnosis were included in this study. Among them, 23 (25.27%) patients met the diagnostic criteria of ET with CVST for inclusion, 14 (60.87%) of whom were females, with a median age of 34 (range 25– 50). CVST diagnosis was made concomitantly to ET in 19 patients (82.61%). The most common symptom and sites of thrombosis of CVST was an acute or subacute headache and sigmoid sinuses, respectively. Compared with ET patients without CVST, ET patients with CVST were significantly younger (37.65± 14.45 vs 60.93± 13.46, P< 0.001) and had lower prevalence of hypertension (4.34 vs 32.35%, P=0.003) and coronary artery disease (0 vs 14.71%, P = 0.045). Patients with CVST presented with significant lower platelet count (510.39± 176.71 vs 750.82± 249.10, P< 0.001) and higher score of IPSET-thrombosis (P=0.017). Multivariate logistic regression analysis indicated that age (P=0.002, OR 1.096, 95% CI 1.035– 1.161), at least one CVRF (P = 0.024, OR 0.037, 95% CI 0.002– 0.649), platelet count (P=0.045, OR 0.994, 95% CI 0.989– 1.001), and lower percentage of antiplatelet therapy (P=0.035, OR 0.307, 95% CI 0.001-1.280) significantly contributed to the risk of CVST in ET. Conclusion: Most patients (95.65%) had a favorable outcome without recurrence after standard anticoagulant and cytoreductive treatment at last follow-up. These findings indicate that CVST may be the initial presentation of ET, with its detection crucial for early diagnosis and appropriate management. Anticoagulant and cytoreductive therapies should be recommended for preventing ET-related CVST with JAK2 V617F mutation.
- 1 April 2021
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 17, 1195-1206
Open AccessClinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia
Background and Objective: Essential thrombocythemia (ET) is a rare cause of cerebral venous sinus thrombosis (CVST). Analysis of the risk factors and treatment therapies of CVST in ET has yielded controversial findings. Subjects and Methods: We retrospectively investigated the clinical characteristics of CVST events in ET and compared baseline characteristics, causative factors, hematological effects, and treatments between ET patients with and without CVST. Results: Overall, 91 of 115 patients who met the ET diagnosis were included in this study. Among them, 23 (25.27%) patients met the diagnostic criteria of ET with CVST for inclusion, 14 (60.87%) of whom were females, with a median age of 34 (range 25– 50). CVST diagnosis was made concomitantly to ET in 19 patients (82.61%). The most common symptom and sites of thrombosis of CVST was an acute or subacute headache and sigmoid sinuses, respectively. Compared with ET patients without CVST, ET patients with CVST were significantly younger (37.65± 14.45 vs 60.93± 13.46, P< 0.001) and had lower prevalence of hypertension (4.34 vs 32.35%, P=0.003) and coronary artery disease (0 vs 14.71%, P = 0.045). Patients with CVST presented with significant lower platelet count (510.39± 176.71 vs 750.82± 249.10, P< 0.001) and higher score of IPSET-thrombosis (P=0.017). Multivariate logistic regression analysis indicated that age (P=0.002, OR 1.096, 95% CI 1.035– 1.161), at least one CVRF (P = 0.024, OR 0.037, 95% CI 0.002– 0.649), platelet count (P=0.045, OR 0.994, 95% CI 0.989– 1.001), and lower percentage of antiplatelet therapy (P=0.035, OR 0.307, 95% CI 0.001-1.280) significantly contributed to the risk of CVST in ET. Conclusion: Most patients (95.65%) had a favorable outcome without recurrence after standard anticoagulant and cytoreductive treatment at last follow-up. These findings indicate that CVST may be the initial presentation of ET, with its detection crucial for early diagnosis and appropriate management. Anticoagulant and cytoreductive therapies should be recommended for preventing ET-related CVST with JAK2 V617F mutation.